# Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations

Source: https://onco.cc/trials/nct06041776/  
OnCo record `nct06041776` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Icotinib in non-small-cell lung cancer and small-cell lung cancer, run by Betta Pharmaceuticals Co., Ltd., now recruiting.

## Summary

Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations is a phase 3 interventional study registered as NCT06041776 by Betta Pharmaceuticals Co., Ltd., with 570 participants planned, started 2023-03-28 and due to reach its primary completion in 2028-04-30. Interventions recorded: Befotertinib + Icotinib placebo, Icotinib + Befotertinib placebo. Conditions listed: Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06041776
- Phase: 3
- Setting: A Multicenter, Randomized, Controlled, Double Blind, Double Simulated, Phase III Clinical Study of Befotertinib vs Icotinib for Postoperative Adjuvant Treatment of IB-IIIB (T3N2M0) Stage Non Small Cell Lung Cancer With Positive EGFR Sensitive Mutations
- Sponsor: Betta Pharmaceuticals Co., Ltd.
- Enrolled: 570

## Sources

- ClinicalTrials.gov NCT06041776: https://clinicaltrials.gov/study/NCT06041776

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Icotinib](https://onco.cc/drugs/icotinib/)
- companies: [Betta Pharmaceuticals](https://onco.cc/companies/betta/)

---
JSON: https://onco.cc/api/v1/entities/nct06041776.json